Board of Directors
[section]
John Bedard, Member of the Scientific Advisory Board
John recently retired from Bristol-Myers Squibb where he was Vice President, FDA Liaison and Global Strategy. He spent the last 15 years of his career at BMS directing development and registration programs for phases I-IV. He also directed the worldwide GLP and GCP programs. Earlier in his career John was Group Director, U.S. Regulatory Affairs at Smith Kline and French Laboratories and Assistant Director, the U.S. Regulatory Affairs at Wyeth-Ayerst.
Over his 25-year career, John has directed development and registration programs in hypertension, heart failure, post-MI therapy, hyperlipidemia, type II diabetes, ulcer disease, psoriasis, migraine, and female hirsutism. A partial list of development programs included in John’s experience are: Pravachol for hyperlipidemia, primary and secondary prevention of MI, stroke and revascularization; Capoten for post MI and diabetic nephropathy; Monopril for hypertension; Avapro for hypertension; Glucovance for type II diabetes; Glucophage XR for type II diabetes; Dovonex for psoriasis; Vaniqa for female hirsutism; Tagamet for stress related bleeding; Tagamet QD for gastric ulcer; Inderal for post MI; and Inderal LA for hypertension, angina and migraine.
John has contributed to DIA, PERI and other associations devoted to education in drug development and registration. He was Lecturer, DIA Course on INDs and NDAs, Lecturer – PERI Course: How to Prepare for FDA Advisory Committee Meetings. Furthermore, he was Chairman, Delaware Valley Regulatory Affairs, as well as Chairman, DIA Special Interest Advisory Committee for Regulatory Affairs. John is a member of DIA, NY Academy of Sciences, and American Association for the Advancement of Science (AAAS). He received a BA in Chemistry from Rutgers University and an M.S. in Chemistry from St. Josephs’ University.
[hr]
[/section]
[section]
Carolyn Maduza, Senior Operating Executive, BOD and Advisory
Most recently, Carolyn served as Interim CFO to GenMark Diagnostics, a publically traded NASDAQ/AIM medical device company. She developed the long term business plan for fund raising and assisted in restructuring the organization to optimize operating efficiencies, reduce costs and simplify international tax reporting. Carolyn completed the company’s first 10-K, Annual Report and Proxy filing. She negotiated global manufacturing and distribution agreements, initiated company-wide operating process mapping to facilitate SOX and revamped sales contracts to align with company’s business and financial model.
Carolyn also consulted as CFO for Helixis, an early-stage manufacturer of advanced nucleic and acid analysis instrumentation and reagents for research and clinical applications. She assisted the company in building its business plan, raised $16 Million in debt and equity, and assisted in the successful sale of the company to Illumina for a 6x return to investors.
Carolyn was the Chief Operating Officer for Sidney Kimmel Cancer Center. Reporting to the Board of Trustees, she evaluated the underperforming Center’s operational/financial condition, assisted the BOT in restructuring the executive leadership, participated in merger discussions, and improved the Center’s operating performance from a 25% decline in net assets to interim fiscal integrity.
Prior to this role, Carolyn was Executive Vice President and Chief Financial Officer at Alteer Corporation, a leading provider of healthcare information technology solutions. She contributed to a 45% growth in revenue and 40% improvement in financial performance by implementing a strategic plan and business model that focused on direct selling and consistent pricing, cost containment and aggressive cash management. She also raised $22 million in venture capital and bank financing and negotiated contracts with Microsoft, WebMD, MedSoft, and the American Medical Association.
Before Alteer, Carolyn utilized her experience in operations, finance and human resources as Senior Vice President and Chief Financial Officer for Stratagene Holding Corporation, a global $65 million privately-held life sciences company. While positioning the company to go public, Carolyn implemented favorable domestic and international tax strategies, renegotiated $40 million in subordinated debt, bonds, loans and lines of credit, and revitalized the Company’s product lines and European operations, achieving a 65% increase in operating income.
Carolyn also served as Chief Financial Officer at Peerless Systems Corporation, a $42 million NASDAQ listed provider of embedded imaging and networking systems. Responsible for business development, financial leadership, and operational control, Carolyn negotiated and integrated two corporate acquisitions that improved revenue by 40%, implemented a long-term incentive plan for key executives, and increased the stock option plan to accommodate growth.
Early in her career, Carolyn gained invaluable experience as Managing Director at MASI, Ltd where she negotiated buy-sell transactions for a 32 member investment banking consortium. She also served as Senior EDP Auditor and Systems Analyst for Arthur Andersen & Company; Assistant Treasurer at Chase Manhattan Bank; Vice President at Mellon Bank; Manager, Midwest Region Capital Markets Group at Grant Thornton International; and SVP, Chief Financial Officer at U.S. Communications.
Carolyn earned a Masters of International Management, with distinction, from the American Graduate School of International Management (“Thunderbird”) and a Bachelor of Business Administration degree from the University of Wisconsin-Milwaukee. She is a Certified Public Accountant. She serves on the Board of Directors of Accela, Inc. and the Foundation to Combat Antimicrobial Resistance. Carolyn also serves on the Advisory Boards of AdChoice and Forcura. Carolyn is a domain expert and EIR for CONNECT’s Springboard program, mentoring several companies in the media-IT and healthcare-IT sectors.
[hr]
[/section]
[section]
He also held leadership roles as Chief Medical Officer, SVP and Head of Oncology Research and Development, SVP Cancer Research and SVP Clinical Pharmacology and Discovery Medicine. In those roles he has been responsible for the successful discovery and development of multiple marketed products. He chairs the Global Safety Board and Medical Governance Executive Committee and is a member of other key governance, scientific advisory and investment Boards at GlaxoSmithKline. Perry’s leadership led to the establishment of an end-to-end research and development center in Shanghai. He holds a B.S. from Stanford University and M.D. and Ph.D from the Albert Einstein College of Medicine. Formerly, he was the Lowe Foundation Professor of Neuro-oncology at the University of Texas Southwestern School of Medicine, then Vice President, Cancer Research at Abbott Laboratories.
[hr]
[/section]
[section]
Cecil B. Pickett, Ph.D.; President, Research and Development of Biogen Idec Inc. (September 2006 through October 2009)
Prior to joining Biogen Idec, Dr. Pickett held several senior R&D positions, including Corporate Senior Vice President of Schering-Plough Corp. and President of Schering-Plough Research Institute. Prior to joining Schering-Plough, he held several senior R&D positions at Merck & Co. Dr. Pickett received his B.Sc. in biology from California State University at Hayward and his Ph.D. in cell biology from University of California at Los Angeles. He is a member of the Institute of Medicine of The National Academy of Sciences. Dr. Pickett previously served as a director of Biogen Idec. Board Committees: Compensation and Management Development Committee, Corporate Governance Committee and Science and Technology Committee (Chair).
[hr]
[/section]
[section]
Dr. Reed is the founder and the Chief Executive Officer of the Foundation to Combat Antimicrobial Resistance, a nonprofit product development partnership. The organization’s mission is to facilitate global research and development for, as well as access to, new antimicrobial agents.
Dr. Reed has over 20 years of experience in, and with, pharmaceutical and biotechnology industries. She was partner at two major global retained executive search firms. Following here tenure with those concerns, she established Reed && Associates Executive Search, a global, retained firm specializing in senior level R&D talent for the pharmaceutical industry.
She holds a Ph.D. in Biological Science from Florida State University and earned her A.B. degree with distinction from Sweet Briar College. Early in her career she received a prestigious New Investigator Award from the NIH funding her laboratory.
[/section]